China biopharmaceutical: second generation highly selective P2X3 inhibitor approved clinical trial
Financial Associated Press, Dec. 21 - China biopharmaceutical announced on the Hong Kong stock exchange that the company's second-generation highly selective P2X3 inhibitor (tcr1672) has obtained the drug clinical trial approval notice issued by the China food and Drug Administration and agreed to carry out the clinical trial of refractory chronic cough (RCC) in China.
This text is a result of machine translation.
Related companies：
In-depth
Financials, Communication
Chinese Education Goes Global: Capturing a Trillion-Dollar Market
A TikTok filter challenge called "Mandarin Fruit Voices" has gone viral. Essentially a straightforward Mandarin learning game with crude animations, minimalist gameplay, and fruit-based pronunciation exercises drawn from early childhood education materials, it has nonetheless captivated international users. For those who once struggled with English, the long-held dream of a world united by Chinese now appears increasingly within reach.
Mar 27, 2025 06:55 PM
Briefing Feb 21, 2023 11:10 AM
· Healthcare
We-Linking Raised Over CNY 10 Mn in Angel Round
Briefing Feb 21, 2023 10:07 AM
· Healthcare
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 26, 2022 12:26 PM
Briefing Feb 16, 2023 12:51 PM
· Healthcare
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
Briefing Feb 15, 2023 12:32 PM
· Healthcare
ZD Medtech Raised Over CNY 100 Mn in Series B
Briefing Feb 13, 2023 12:54 PM
· Healthcare
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Briefing Feb 08, 2023 11:44 AM
· Healthcare
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
Briefing Feb 07, 2023 12:11 PM
· Healthcare
ForLong Biotech Nets Over CNY 100 Mn in Series A
Briefing Feb 07, 2023 10:59 AM
· Healthcare
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Briefing Jan 31, 2023 11:02 AM
· Healthcare
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn
Financials
Temasek-Backed Asset Manager Expands to Abu Dhabi, Strengthening Global Footprint
Apr 02, 2025 06:31 PM
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Read next
Insight
In-depth
Automotive · Analysis
Chinese Carmakers Expanding into Europe: Beware of Four Major Misconceptions
Apr 22, 2025 09:32 PM
Insight
In-depth
Consumer Staples · Analysis
Perfect Timing: Chagee Bridges the Cultural Gap in the U.S. Tea Market
Apr 22, 2025 03:29 PM
Insight
In-depth
Automotive · Analysis
Chinese Automakers Break into a €10 Billion Market in Europe
Apr 11, 2025 09:57 PM
Insight
In-depth
Automotive · Analysis
Tariff Escalation Through the Lens of Geopolitical Economy
Apr 11, 2025 12:32 PM
